- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Spinal muscular atrophy (SMA)
- Meeting Date: May 2021
- Public Summary Document (PSD) May 2021 PBAC Meeting - (PDF 2.1MB)
- Public Summary Document (PSD) May 2021 PBAC Meeting - (Word 1MB)
Onasemnogene abeparvovec – May 2021
Onasemnogene abeparvovec: Solution for injection, customised based on patient weight; Zolgensma®
Last updated
10 September 2021